..


Business News

  • Written by Heidi Cuthbert


7 May 2018: Race Oncology Limited (“RAC”) released today a video interview with the Company’s new non-executive director, Dr John Cullity.

Dr Cullity trained as a haematology oncologist and became a specialist in the area of leukaemia. He has also held senior roles with Sanofi-Aventis and Schering-Plough in the US.

Based in New York, Dr Cullity now focuses on M&A and licensing transactions in the biopharma industry.

Commenting on Race Oncology’s first drug, Bisantrene, Dr Cullity said: “There is substantial opportunity for Bisantrene which is led by its activity in acute myeloid leukaemia.”

“Bisantrene has been shown to be active through immune-oncology pathways, which are so relevant to blockbuster agents that are currently being marketed by major pharmaceutical companies,” noted Dr Cullity.

“Additionally, it has unparalleled safety, particularly cardiac safety, which is so relevant and much sought-after by doctors within the anthracycline class.

He concluded: “Altogether, it’s a compelling package.”

In terms of the specific value he brings to the Race board, Dr Cullity noted: “I can help in several ways – firstly, through the evaluation of transactions as they come to light for Bisantrene with mid-to-large pharmaceutical companies.”

“Secondly, as the company considers additional assets that it might bring to build further investor value, I can assist with related assessment and negotiation.”

About Bisantrene

Bisantrene is a small-molecule chemotherapy drug related to the anthracyclines, the most frequently prescribed cancer drugs and first line of treatment for many cancers, but has been shown to have greatly reduced cardiac toxicity. Bisantrene was tested in more than 40 clinical studies before it was lost in a series of pharmaceutical mergers in the 1990s. The initial clinical opportunity for Bisantrene is for relapsed/refractory AML patients. Race owns two patents on the drug, both of which have received notice of allowance in the US, and has been granted an Orphan Drug Designation in the US for AML, which confers seven years of market exclusivity in US from date of FDA approval.

About Race Oncology (RAC.ASX)

Race Oncology is a specialty pharmaceutical company that listed on the Australian Securities Exchange (ASX) in July 2016. Race’s business model is to pursue later-stage drug assets in the cancer field that have been overlooked by big pharma. The company’s first asset is Bisantrene, a chemotherapy drug that was the subject of more than 40 phase II clinical studies during the 1980s and 1990s, then lost in a series of big pharma mergers.

 



g

What is the best structure to use when starting up a business

Coco Hou, tax specialist and accountant, has shared her advice for people who are starting up their own businesses, setting up side gigs, or moving into consultancy work. The start of the new financ...

Leading Employment Firm in WA 2018

Only a certain few start their careers as the boss. For most of us, we get employed by companies and in most cases, we never really find the need to hire employment lawyers. But if we do, hiring an ...

Hertz collaborates with UbiPark to develop simpler mobility solution

Today, smart parking solutions provider UbiPark and leading vehicle rental brand Hertz Australia have announced a strategic collaboration to develop smarter mobility solutions. The collaboration ...

Coalition Government delivers $2.25 million to Queensland Cane Growers’ Organisation

Queensland Sugarcane growers will be able to show big sugar buyers how sustainably their product was grown thanks to a cutting edge project funded by the Coalition Government.   The Sustainable Su...

Danilo de Andrade joins Di Bella Coffee

A leading Brazilian specialty coffee roaster and barista has brought his love of coffee and skills to one of Australia’s most loved coffee brands, Di Bella Coffee in his new role as the company’s Pr...

The Networking Nest - How CoWorking Spaces Can Promote Business Growth

So, what actions are you taking to grow your business? If you were mapping out tools and tricks to help boost your brand and climb to the top of the Australian business world, a CoWorking Space may ...

Politics

Union demands paint a bleak future under Shorten

It’s time for Bill Shorten to come clean and rule out extreme changes to Australia’s industrial relations laws that would wind the clock back to the strike-torn Whitlam era.   As the ACTU prepares...

Doorstop at AKD Sawmill with Trevor Ruthenberg, LNP Candidate for Longman

MR TREVOR RUTHENBERG, LNP CANDIDATE FOR LONGMAN: Well morning folks. Welcome to Caboolture, welcome to Longman. This is a fantastic day for local jobs. This is a fantastic day for our community. ...

Australia’s resource and energy export figures are on track to set a new record

Resources and energy exports setting NEW records   Australia’s resource and energy export figures are on track to set a new record of $226 billion in 2017–18 – and go even higher this year – accor...

Travel

Winter In Rotorua: Things To Do

While many travelers consider the summer months to be the prime traveling season, there are thousands and thousands of travelers who love to take to their campervan hire australia journeys when the ...

Discover Hong Kong Your Way With Ecruising

From July – November 2018, Ecruising in partnership with Hong Kong Tourism and Royal Caribbean, including Azamara and Celebrity Cruises are offering travellers new and exclusive cruising itinerari...

Save on the ultimate family escape at AYANA Resort and Spa, BALI

Re-connect, relax and refresh with a school holiday break that’ll win over the whole family   SYDNEY, Australia – July 2018:  The luxury integrated AYANA Resort and Spa, BALI, overlooking beautifu...

You might also like